DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lqh6p7/antibodydrug) has announced the addition of the "Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis" report to their offering.
This report entitled Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis is based on the analysis of more than 90 companies, more than 100 ADC drug profiles and more than 26 ADC technologies and components.
Sources of information are provided by 274 scientific references and numerous non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets (with hyperlinks leading to source of information). The report also describes and analyzes business deals in the ADC field, e.g. collaboration and license agreements, mergers and acquisitions, financial transactions (divestments, public offerings, private equity and venture capital fund-raising).
Coverage of this ADC report:
- Next-to-market ADCs
- ADC Drug Profiles: clinical, pre-IND, preclinical
- Target Competition by ADCs
- ADC Development Failures
- Conventional & Emerging ADC Technologies
- Polymeric ADC Carriers
- Novel ADC Payloads & Linkers
- Site-specific ADC Conjugation Technologies
- Major Pharma & Biotech Companies with ADC Programs
- Small and Medium Biopharmaceutical Companies with ADC Programs
- Integrated ADC Technology & Pipeline Companies
- Companies with Linker, Payload, Carrier and Conjugation Technologies
- Commercial Opportunities and Perspectives with ADCs
- Commericalization of Approved ADCs
- Fund-Raising for ADC Companies
- Pharma-Biotech & Biotech-Biotech Collaboration & Licensing Agreements
Companies Mentioned Include:
- 3SBio
- ACES Pharma
- ADC Therapeutics
- APO-T
- AbbVie
- Ablynx
- Asana Biosciences
- Astellas Pharma
- AstraZeneca
- NBE Therapeutics
- NanoCarrier
- Nerviano Medical Sciences
- Novartis
- OntoChem
- Oxford BioTherapeutics
- Oxis Biotech
- Zhejiang Medicine Co.
- Zova Biotherapeutics
- Zymeworks
Report Structure:
1 Executive Summary
2 ADC Pipeline Analysis
3 ADC Technology Analysis
4 ADC Stakeholder Analysis
5 ADC Business Analysis
6 ADC Drug Profiles
7 ADC Company Profiles
8 References
9 ADDENDUM
10 Tables
For more information visit http://www.researchandmarkets.com/research/lqh6p7/antibodydrug
